Evidence mapPaperPMID 40830968Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.

Seif Ehab, Ola A Gaser, Atif Abdulwahab A Oyouni, Nader Kameli, Faisal Alzahrani, Ahmed Abdal Dayem

Abstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seif EhabBiomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt.ORCID 0000-0003-1906-4269
Ola A GaserBiomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt.ORCID 0009-0007-7458-0879
Atif Abdulwahab A OyouniDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.ORCID 0000-0001-8762-4999
Nader KameliDepartment of Medical Laboratory Technology, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0003-3709-6993
Faisal AlzahraniKing Fahd Medical Research Center, Embryonic Stem Cells Unit, Department of Biochemistry, Faculty of Science, King AbdulAziz University, Jeddah, Saudi Arabia.ORCID 0000-0003-0441-4000
Ahmed Abdal DayemStem Cell and Regenerative Biotechnology Major, School of Advanced Biotechnology, College of Institute of Science and Technology, Molecular & Cellular Reprogramming Center, Institute of Advanced Regenerative Science, Institute of Health, Aging & Society, Konkuk University, Seoul, Republic of Korea.ORCID 0000-0003-3873-9903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arthritic diseases are a significant global health challenge, highlighting the urgent need for innovative therapeutic strategies. Extracellular vesicles (EVs) have emerged as promising candidates for treating various intractable diseases. This review explores the therapeutic potential of engineered EVs in joint diseases, particularly in comparison to their parental stem cells. Recent research underscores the efficacy of EVs in treating joint diseases, especially Osteoarthritis (OA). We discuss EV engineering strategies aimed at overcoming the limitations of natural EVs. Data from preclinical trials, clinical studies, and in vitro and in vivo reports are analyzed to evaluate the effectiveness of EVs in treating joint conditions. In addition to their role in intercellular communication, EVs influence various biological processes crucial for bone remodeling, cartilage regeneration, immunomodulation, and inflammation control. EVs are rich in vital biomolecules such as proteins, microRNAs (miRNA), lipids, and nucleic acids, which enhance their therapeutic potential compared to parental stem cells. This understanding is key to developing targeted and effective engineered EVs for OA and other joint diseases. A comprehensive grasp of EV engineering and underlying mechanisms will pave the way for novel and efficient therapies for arthritic diseases and related conditions. This article is categorized under: Implantable Materials and Surgical Technologies > Nanotechnology in Tissue Repair and Replacement Nanotechnology Approaches to Biology > Cells at the Nanoscale Biology-Inspired Nanomaterials > Peptide-Based Structures.

Indexed as

Extracellular VesiclesOsteoarthritisAnimalsHumansarthritic diseasescell free therapydeliveryengineeringextracellular vesiclesstem cells

Identifiers

PMID40830968
PMCPMC12365376

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.